Leflunomide or methotrexate for juvenile rheumatoid arthritis.

  title={Leflunomide or methotrexate for juvenile rheumatoid arthritis.},
  author={Earl Silverman and Richard Mouy and Lynn R. Spiegel and Lawrence K Jung and Rotraud Katharina Saurenmann and Pekka Lahdenne and Gerd Horneff and Immaculada Calvo and Ilona S. Szer and Karen M Simpson and John A. Stewart and Vibeke Strand},
  journal={The New England journal of medicine},
  volume={352 16},
BACKGROUND We compared the safety and efficacy of leflunomide with that of methotrexate in the treatment of polyarticular juvenile rheumatoid arthritis in a multinational, randomized, controlled trial. METHODS Patients 3 to 17 years of age received leflunomide or methotrexate for 16 weeks in a double-dummy, blinded fashion, followed by a 32-week blinded extension. The rates of American College of Rheumatology Pediatric 30 percent responses (ACR Pedi 30) and the Percent Improvement Index were… CONTINUE READING